Search Results - "Kendra, Kari"

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function by Stiff, Andrew, Trikha, Prashant, Mundy-Bosse, Bethany, McMichael, Elizabeth, Mace, Thomas A, Benner, Brooke, Kendra, Kari, Campbell, Amanda, Gautam, Shalini, Abood, David, Landi, Ian, Hsu, Vincent, Duggan, Megan, Wesolowski, Robert, Old, Matthew, Howard, John Harrison, Yu, Lianbo, Stasik, Nancy, Olencki, Thomas, Muthusamy, Natarajan, Tridandapani, Susheela, Byrd, John C, Caligiuri, Michael, Carson, William E

“…mAbs are used to treat solid and hematologic malignancies and work in part through Fc receptors (FcRs) on natural killer cells (NK). However, FcR-mediated…”
Get full text

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma by Patel, Sapna P., Othus, Megan, Chen, Yuanbin, Wright, G. Paul, Yost, Kathleen J., Hyngstrom, John R., Hu-Lieskovan, Siwen, Lao, Christopher D., Fecher, Leslie A., Truong, Thach-Giao, Eisenstein, Jennifer L., Chandra, Sunandana, Sosman, Jeffrey A., Kendra, Kari L., Wu, Richard C., Devoe, Craig E., Deutsch, Gary B., Hegde, Aparna, Khalil, Maya, Mangla, Ankit, Reese, Amy M., Ross, Merrick I., Poklepovic, Andrew S., Phan, Giao Q., Onitilo, Adedayo A., Yasar, Demet G., Powers, Benjamin C., Doolittle, Gary C., In, Gino K., Kokot, Niels, Gibney, Geoffrey T., Atkins, Michael B., Shaheen, Montaser, Warneke, James A., Ikeguchi, Alexandra, Najera, Jose E., Chmielowski, Bartosz, Crompton, Joseph G., Floyd, Justin D., Hsueh, Eddy, Margolin, Kim A., Chow, Warren A., Grossmann, Kenneth F., Dietrich, Eliana, Prieto, Victor G., Lowe, Michael C., Buchbinder, Elizabeth I., Kirkwood, John M., Korde, Larissa, Moon, James, Sharon, Elad, Sondak, Vernon K., Ribas, Antoni

“…Patients who received 3 doses of pembrolizumab before surgery and 15 doses after surgery had significantly longer event-free survival than those who received…”
Get full text

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma by RIBAS, Antoni, KEFFORD, Richard, LORIGAN, Paul, KENDRA, Kari L, MAIO, Michele, TREFZER, Uwe, SMYLIE, Michael, MCARTHUR, Grant A, DRENO, Brigitte, NATHAN, Paul D, MACKIEWICZ, Jacek, KIRKWOOD, John M, MARSHALL, Margaret A, GOMEZ-NAVARRO, Jesus, BO HUANG, PAVLOV, Dmitri, HAUSCHILD, Axel, PUNT, Cornelis J. A, HAANEN, John B, MARMOL, Maribel, GARBE, Claus, GOGAS, Helen, SCHACHTER, Jacob, LINETTE, Gerald

“…In phase I/II trials, the cytotoxic T lymphocyte-associated antigen-4-blocking monoclonal antibody tremelimumab induced durable responses in a subset of…”
Get full text

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134 by Atkins, Michael B, Lee, Sandra J, Chmielowski, Bartosz, Tarhini, Ahmad A, Cohen, Gary I, Truong, Thach-Giao, Moon, Helen H, Davar, Diwakar, O'Rourke, Mark, Stephenson, Joseph J, Curti, Brendan D, Urba, Walter J, Brell, Joanna M, Funchain, Pauline, Kendra, Kari L, Ikeguchi, Alexandra P, Jaslowski, Anthony, Bane, Charles L, Taylor, Mark A, Bajaj, Madhuri, Conry, Robert M, Ellis, Robert J, Logan, Theodore F, Laudi, Noel, Sosman, Jeffrey A, Crockett, David G, Pecora, Andrew L, Okazaki, Ian J, Reganti, Sowjanya, Chandra, Sunandana, Guild, Samantha, Chen, Helen X, Streicher, Howard Z, Wolchok, Jedd D, Ribas, Antoni, Kirkwood, John M

“…Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in…”
Get full text

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis by Abu-Sbeih, Hamzah, Ali, Faisal S, Naqash, Abdul Rafeh, Owen, Dwight H, Patel, Sandipkumar, Otterson, Gregory A, Kendra, Kari, Ricciuti, Biagio, Chiari, Rita, De Giglio, Andrea, Sleiman, Joseph, Funchain, Pauline, Wills, Beatriz, Zhang, Jiajia, Naidoo, Jarushka, Philpott, Jessica, Gao, Jianjun, Subudhi, Sumit K, Wang, Yinghong

“…Immune checkpoint inhibitor (ICI) therapy often is suspended because of immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors…”
Get full text

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609 by Tarhini, Ahmad A, Lee, Sandra J, Hodi, F Stephen, Rao, Uma N M, Cohen, Gary I, Hamid, Omid, Hutchins, Laura F, Sosman, Jeffrey A, Kluger, Harriett M, Eroglu, Zeynep, Koon, Henry B, Lawrence, Donald P, Kendra, Kari L, Minor, David R, Lee, Carrie B, Albertini, Mark R, Flaherty, Lawrence E, Petrella, Teresa M, Streicher, Howard, Sondak, Vernon K, Kirkwood, John M

“…Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI)…”
Get full text

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma by Schwartzentruber, Douglas J, Lawson, David H, Richards, Jon M, Conry, Robert M, Miller, Donald M, Treisman, Jonathan, Gailani, Fawaz, Riley, Lee, Conlon, Kevin, Pockaj, Barbara, Kendra, Kari L, White, Richard L, Gonzalez, Rene, Kuzel, Timothy M, Curti, Brendan, Leming, Phillip D, Whitman, Eric D, Balkissoon, Jai, Reintgen, Douglas S, Kaufman, Howard, Marincola, Francesco M, Merino, Maria J, Rosenberg, Steven A, Choyke, Peter, Vena, Don, Hwu, Patrick

“…In patients with metastatic melanoma, addition of a gp100 peptide vaccine to high-dose interleukin-2 doubled response rates, delayed disease progression by a…”
Get full text

Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma by Mantopoulos, Dimosthenis, Kendra, Kari L, Letson, Alan D, Cebulla, Colleen M

Get more information

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial by VanderWalde, Ari, Bellasea, Shay L., Kendra, Kari L., Khushalani, Nikhil I., Campbell, Katie M., Scumpia, Philip O., Kuklinski, Lawrence F., Collichio, Frances, Sosman, Jeffrey A., Ikeguchi, Alexandra, Victor, Adrienne I., Truong, Thach-Giao, Chmielowski, Bartosz, Portnoy, David C., Chen, Yuanbin, Margolin, Kim, Bane, Charles, Dasanu, Constantin A., Johnson, Douglas B., Eroglu, Zeynep, Chandra, Sunandana, Medina, Egmidio, Gonzalez, Cynthia R., Baselga-Carretero, Ignacio, Vega-Crespo, Agustin, Garcilazo, Ivan Perez, Sharon, Elad, Hu-Lieskovan, Siwen, Patel, Sapna P., Grossmann, Kenneth F., Moon, James, Wu, Michael C., Ribas, Antoni

“…In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in…”
Get full text

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival by Haddad, Tyler C., Zhao, Songzhu, Li, Mingjia, Patel, Sandip H., Johns, Andrew, Grogan, Madison, Lopez, Gabriella, Miah, Abdul, Wei, Lai, Tinoco, Gabriel, Riesenberg, Brian, Li, Zihai, Meara, Alexa, Bertino, Erin M., Kendra, Kari, Otterson, Gregory, Presley, Carolyn J., Owen, Dwight H.

“…Introduction Immune checkpoint inhibitors (ICI) are associated with unique immune-related adverse events (irAEs). Immune-related thrombocytopenia (irTCP) is an…”
Get full text

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications by Spakowicz, Daniel, Hoyd, Rebecca, Muniak, Mitchell, Husain, Marium, Bassett, James S, Wang, Lei, Tinoco, Gabriel, Patel, Sandip H, Burkart, Jarred, Miah, Abdul, Li, Mingjia, Johns, Andrew, Grogan, Madison, Carbone, David P, Verschraegen, Claire F, Kendra, Kari L, Otterson, Gregory A, Li, Lang, Presley, Carolyn J, Owen, Dwight H

“…The microbiome has been shown to affect the response to Immune Checkpoint Inhibitors (ICIs) in a small number of cancers and in preclinical models. Here, we…”
Get full text

Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases by Williams, Noelle L., Wuthrick, Evan J., Kim, Hyun, Palmer, Joshua D., Garg, Shivank, Eldredge-Hindy, Harriet, Daskalakis, Constantine, Feeney, Kendra J., Mastrangelo, Michael J., Kim, Lyndon J., Sato, Takami, Kendra, Kari L., Olencki, Thomas, Liebner, David A., Farrell, Christopher J., Evans, James J., Judy, Kevin D., Andrews, David W., Dicker, Adam P., Werner-Wasik, Maria, Shi, Wenyin

“…We performed a phase 1 study to determine the maximum tolerable dose and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain radiation…”
Get full text

Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit by Grossman, Douglas, Okwundu, Nwanneka, Bartlett, Edmund K, Marchetti, Michael A, Othus, Megan, Coit, Daniel G, Hartman, Rebecca I, Leachman, Sancy A, Berry, Elizabeth G, Korde, Larissa, Lee, Sandra J, Bar-Eli, Menashe, Berwick, Marianne, Bowles, Tawnya, Buchbinder, Elizabeth I, Burton, Elizabeth M, Chu, Emily Y, Curiel-Lewandrowski, Clara, Curtis, Julia A, Daud, Adil, Deacon, Dekker C, Ferris, Laura K, Gershenwald, Jeffrey E, Grossmann, Kenneth F, Hu-Lieskovan, Siwen, Hyngstrom, John, Jeter, Joanne M, Judson-Torres, Robert L, Kendra, Kari L, Kim, Caroline C, Kirkwood, John M, Lawson, David H, Leming, Philip D, Long, Georgina V, Marghoob, Ashfaq A, Mehnert, Janice M, Ming, Michael E, Nelson, Kelly C, Polsky, David, Scolyer, Richard A, Smith, Eric A, Sondak, Vernon K, Stark, Mitchell S, Stein, Jennifer A, Thompson, John A, Thompson, John F, Venna, Suraj S, Wei, Maria L, Swetter, Susan M

“…Use of prognostic gene expression profile (GEP) testing in cutaneous melanoma (CM) is rising despite a lack of endorsement as standard of care. To develop…”
Get more information

Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer by Johns, Andrew C, Yang, Mike, Wei, Lai, Grogan, Madison, Spakowicz, Daniel, Patel, Sandipkumar H, Li, Mingjia, Husain, Marium, Kendra, Kari L, Otterson, Gregory A, Rosko, Ashley E, Andersen, Barbara L, Carbone, David P, Owen, Dwight H, Presley, Carolyn J

“…Abstract Objectives Immune checkpoint inhibitor immunotherapy (IO) is revolutionizing cancer care but can lead to significant toxicity. This study seeks to…”
Get full text

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers by Algazi, Alain P., Moon, James, Lao, Christopher D., Chmielowski, Bartosz, Kendra, Kari L., Lewis, Karl D., Gonzalez, Rene, Kim, Kevin, Godwin, John E., Curti, Brendan D., Latkovic‐Taber, Michaella, Lomeli, Shirley H., Gufford, Brandon T., Scumpia, Philip O., Lo, Roger S., Othus, Megan, Ribas, Antoni

“…Background Aberrant PI3K/AKT signaling in BRAF‐mutant cancers contributes to resistance to BRAF inhibitors. The authors examined dual MAPK and PI3K pathway…”
Get full text

Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review by Patel, Shivani, Armbruster, Heather, Pardo, Gretchen, Archambeau, Brianna, Kim, Na Hyun, Jeter, Joanne, Wu, Richard, Kendra, Kari, Contreras, Carlo M, Spaccarelli, Natalie, Dulmage, Brittany, Pootrakul, Llana, Carr, David R, Verschraegen, Claire

“…Basal cell carcinoma (BCC) is highly curable by surgical excision or radiation. In rare cases, BCC can be locally destructive or difficult to surgically…”
Get full text

Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase by Savardekar, Himanshu, Allen, Carter, Jeon, Hyeongseon, Li, Jianying, Quiroga, Dionisia, Schwarz, Emily, Wu, Richard C, Zelinskas, Sara, Lapurga, Gabriella, Abreo, Alexander, Stiff, Andrew, Shaffer, Jami, Blaser, Bradley W, Old, Matthew, Wesolowski, Robert, Xin, Gang, Kendra, Kari L, Chung, Dongjun, Carson, 3rd, William E

“…Myeloid-derived suppressor cell (MDSC) levels are elevated in patients with cancer and contribute to reduced efficacy of immune checkpoint therapy. MDSC…”
Get more information

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report by Chitnis, Saurabh D, Seim, Nolan B, Kendra, Kari

“…Mucosal melanoma, an aggressive type of malignancy different from the cutaneous melanomas commonly seen in the head and neck region, represents < 1% of all…”
Get full text

Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy by Johns, Andrew C., Yang, Mike, Wei, Lai, Grogan, Madison, Patel, Sandipkumar H., Li, Mingjia, Husain, Marium, Kendra, Kari L., Otterson, Gregory A., Burkart, Jarred T., Spakowicz, Daniel, Hoyd, Rebecca, Owen, Dwight H., Presley, Carolyn J.

“…Background and objectives Medical comorbidities (MC) are highly prevalent among patients with cancer and predict worse outcomes for traditional therapies. This…”
Get full text

BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy by Sun, Steven H., Angell, Colin D., Savardekar, Himanshu, Sundi, Debasish, Abood, David, Benner, Brooke, DiVincenzo, Mallory J., Duggan, Megan, Choueiry, Fouad, Mace, Thomas, Trikha, Prashant, Lapurga, Gabriella, Johnson, Courtney, Carlson, Erick J., Chung, Catherine, Peterson, Blake R., Lianbo Yu, Zhao, Jing, Kendra, Kari L., Carson, William E.

“…Myeloid-derived suppressor cells (MDSC) have been linked to loss of immune effector cell function through a variety of mechanisms such as the generation of…”
Get full text